ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), a prominent global biopharmaceutical company dedicated to pioneering advancements in treating ophthalmic and neuro-ophthalmic diseases, has announced the continuation of the esteemed Ramin Tadayoni Award in collaboration with EURETINA. This award is a tribute to Professor Ramin Tadayoni, the esteemed Chief Scientific Officer of Oculis and a globally recognized expert in retinal health, who sadly passed away unexpectedly on April 19, 2024.

The Ramin Tadayoni Award serves to celebrate Prof. Tadayoni's enduring legacy, which has significantly influenced the field of retinal research and treatment. The award is designed to inspire and support innovative research efforts that aim to enhance our understanding of retinal diseases, with the potential to lead to groundbreaking treatments. As an annual initiative, the award offers a total of 30,000 dedicated to research support, alongside an additional 5,000 for the recipient's candidate, thereby recognizing and nurturing the talents of emerging ophthalmologists.

Applications for this years award will remain open until May 12, 2025, and the recipient will be honored during the opening ceremony of the EURETINA Congress set to take place in Paris from September 4 to 7, 2025. This recognition is a significant opportunity for postgraduate scholars specializing in retina research, highlighting Oculis commitment to fostering the next generation of leaders in ophthalmology.

Riad Sherif, M.D., the Chief Executive Officer of Oculis, expressed profound respect for Prof. Tadayonis legacy, stating: As we approach the one-year anniversary of Prof. Tadayoni's passing on April 19, we are deeply honored to continue our support for this award. It commemorates not only a remarkable friend and scientist but also a cherished member of the global retina community and our Oculis family. The impact Prof. Tadayoni had on ophthalmology and our research pipeline is immeasurable. Through this award, we are committed to carrying forward his passion for scientific inquiry, education, and patient-centered innovation. His unwavering dedication to retinal research serves as an inspiring beacon for us and the upcoming generation of clinicians and researchers who are devoted to transforming patient care for those suffering from blinding diseases.

In response to the announcement, Anat Loewenstein, M.D., the President of EURETINA, stated: We are honored to continue the establishment of the Ramin Tadayoni Award for a second year, paying tribute to an extraordinary individual whose legacy has a lasting impact on retinal research and patient care. This award symbolizes Prof. Tadayonis significant contributions to ophthalmology, alongside his remarkable role as a mentor and respected colleague. By promoting excellence in retinal research, we strive to uphold his vision and continue nurturing the future leaders of our field. We are thankful to Oculis for their steadfast support of this important initiative.

Dr. Andrea Govetto, M.D., Ph.D., was celebrated as the inaugural recipient of the Ramin Tadayoni Award in 2024. Dr. Govetto, who serves as a vitreoretinal surgeon at the Oftalmico-Fatebenefratelli Hospital in Milan, Italy, is currently working on a groundbreaking project that develops a computational model to better understand fluid flow and retinal tissue deformation in macular edema, a common condition that can lead to vision loss.

Professor Tadayoni was a distinguished member of Oculis Scientific Advisory Board, having joined in December 2017 and later being appointed as Chief Scientific Officer in February 2024. At the time of his appointment, he was also the President of EURETINA and served as the Chairman of the Retina Department at the Rothschild Foundation Hospital, as well as being affiliated with the French Myopia Institute. His impressive career included significant roles as Chief of the Department of Lariboisire University Hospitals and Saint-Louis Hospital and as a Professor of Ophthalmology at the University of Paris-Cit. Prof. Tadayoni contributed to numerous clinical trials and advised several companies in the ophthalmology sector for over two decades. His extensive publication record includes over 320 medical and scientific articles, contributing significantly to ophthalmology textbooks. Among his accolades are the prestigious American Academy of Ophthalmology Achievement Award and the esteemed Jules Gonin Award from the Retina Research Foundation. He earned his medical degree from Paris V University and completed a fellowship in retina at Lariboisire University Hospital while pursuing a Ph.D. in Science at Paris VII University and the Paris Vision Institute.

About Oculis
Oculis is a cutting-edge global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) devoted to enhancing eye care and preserving vision. The company boasts a robust pipeline of innovative product candidates currently in clinical development, such as OCS-01, a topical eye drop candidate aimed at treating diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with prospects for broader applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNF eye drop candidate for dry eye disease (DED). Oculis is headquartered in Switzerland while maintaining operations in both the U.S. and Iceland and is guided by a seasoned management team with a proven track record in the industry, supported by leading international healthcare investors.

For further information, please visit: